(Q37711274)

22 August 2017

1 reference

title

Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection (English)

1 reference

22 August 2017

1 reference

1 reference

1 reference

1 reference

1

0 references

author name string

George K K Lau

series ordinal

2

1 reference

PubMed ID

20238245

22 August 2017

Jia-Horng Kao

series ordinal

3

1 reference

PubMed ID

20238245

22 August 2017

Edward Gane

series ordinal

4

1 reference

22 August 2017

18 March 2010

1 reference

Digestive Diseases and Sciences

22 August 2017

1 reference

22 August 2017

55

1 reference

22 August 2017

10

1 reference

22 August 2017

2727-2734

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-010-1179-4

22 August 2017

0 references

cites work

The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-010-1179-4

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10620-010-1179-4

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

21 January 2018

1 reference

12 December 2020

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

12 December 2020

Hepatitis B surface antigen seroclearance during chronic HBV infection

1 reference

12 December 2020

Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers

1 reference

12 December 2020

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

1 reference

12 December 2020

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

1 reference

12 December 2020

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

1 reference

12 December 2020

Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion

1 reference

12 December 2020

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

12 December 2020

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

12 December 2020

HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.

1 reference

12 December 2020

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

1 reference

12 December 2020

Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion

1 reference

12 December 2020

Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine

1 reference

12 December 2020

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

1 reference

12 December 2020

Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion

1 reference

12 December 2020

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

12 December 2020

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

12 December 2020

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

12 December 2020

Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion

1 reference

12 December 2020

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

12 December 2020

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

1 reference

12 December 2020

Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels

1 reference

12 December 2020

Chronic hepatitis B: update 2009

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

12 December 2020

Update on viral hepatitis: 2008.

1 reference

12 December 2020

The economics of treating chronic hepatitis B in Asia

1 reference

12 December 2020

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

1 reference

12 December 2020

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

12 December 2020

Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F

1 reference

12 December 2020

Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B

1 reference

12 December 2020

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

1 reference

12 December 2020

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

12 December 2020

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

12 December 2020

Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.

1 reference

12 December 2020

New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response

1 reference

12 December 2020

Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B

1 reference

12 December 2020

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

12 December 2020

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

12 December 2020

Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients

1 reference

12 December 2020

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

1 reference

12 December 2020

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

12 December 2020

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

12 December 2020

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

12 December 2020

Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus

1 reference

12 December 2020

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

1 reference

12 December 2020

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

12 December 2020

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

12 December 2020

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

12 December 2020

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

12 December 2020

HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up

1 reference

12 December 2020

Role of viral factors in the natural course and therapy of chronic hepatitis B.

1 reference

12 December 2020

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Economic evaluation of the societal costs of hepatitis B in South Korea.

1 reference

12 December 2020

Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.

1 reference

12 December 2020

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

12 December 2020

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

12 December 2020

Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion

1 reference

12 December 2020

Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia

1 reference

12 December 2020

10.1007/S10620-010-1179-4

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20238245